Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | RP-3500 |
| Synonyms | |
| Therapy Description |
RP-3500 binds to and inhibits ATR, which may lead to decreased downstream signaling and inhibition of tumor growth (PMID: 34911817). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| RP-3500 | RP 3500|RP3500|Camonsertib | ATR Inhibitor 16 | RP-3500 binds to and inhibits ATR, which may lead to decreased downstream signaling and inhibition of tumor growth (PMID: 34911817). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ATM R3008H | prostate cancer | predicted - sensitive | RP-3500 | Case Reports/Case Series | Actionable | In a Phase I/II trial (TRESR), RP-3500 treatment resulted in a 29% tumor reduction in a castration-resistant prostate cancer patient harboring ATM R3008H, who remained on treatment for more than 61 weeks (PMID: 37277454; NCT04497116). | 37277454 |
| RAD51C inact mut | ovarian cancer | predicted - sensitive | RP-3500 | Case Reports/Case Series | Actionable | In a Phase I/II trial (TRESR), RP-3500 treatment resulted in a partial response with complete resolution of the target lesion at 19 weeks in a patient with ovarian cancer harboring a RAD51C inactivating mutation (PMID: 37277454; NCT04497116). | 37277454 |
| ATM Q1919P | lung non-small cell carcinoma | sensitive | RP-3500 | Preclinical - Cell culture | Actionable | In a preclinical study, RP-3500 inhibited viability in a non-small cell lung cancer cell line harboring ATM Q1919P in culture (PMID: 34911817). | 34911817 |
| ATM inact mut | pancreatic cancer | predicted - sensitive | RP-3500 | Case Reports/Case Series | Actionable | In a Phase I/II trial (TRESR), RP-3500 treatment resulted in a partial response at week 54 in a patient with advanced pancreatic cancer harboring a germline ATM frameshift mutation (PMID: 37277454; NCT04497116). | 37277454 |
| ATM inact mut | Advanced Solid Tumor | predicted - sensitive | RP-3500 | Phase Ib/II | Actionable | In a Phase I/II trial (TRESR), RP-3500 treatment resulted in an overall response rate (ORR) of 15% (7/46) and clinical benefit rate of 48% (22/46) in advanced solid tumor patients with ATM inactivation, an ORR of 18% (5/28) with germline ATM loss of function (LOF) mutations, and an ORR of 13% (2/15) with somatic ATM LOF mutations, with benefit in patients with non-small cell lung (n=2), bile duct (3/4), colorectal (3/6), and prostate (4/8) cancers (Ann Oncol (2024) 35 (Suppl_2): S496; NCT04497116). | detail... |
| ATM Q628Pfs*7 ATM I1581Nfs*5 ATM A2843V | colon adenocarcinoma | sensitive | RP-3500 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, RP-3500 inhibited viability in a colon adenocarcinoma cell line harboring ATM Q628Pfs*7, ATM I1581Nfs*5, and ATM A2843V in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 34911817). | 34911817 |
| ATM inact mut | lung non-small cell carcinoma | predicted - sensitive | RP-3500 | Case Reports/Case Series | Actionable | In a Phase I/II trial (TRESR), RP-3500 treatment resulted in a partial response after 37 weeks of treatment in a patient with advanced non-small cell lung cancer harboring germline biallelic ATM inactivation (PMID: 37277454; NCT04497116). | 37277454 |
| ATM loss | stomach cancer | sensitive | RP-3500 | Preclinical - Pdx | Actionable | In a preclinical study, RP-3500 resulted in complete tumor regression in a gastric cancer patient-derived xenograft (PDX) model with biallelic loss of ATM (PMID: 34911817). | 34911817 |
| ATM R2832C | mantle cell lymphoma | sensitive | RP-3500 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, RP-3500 inhibited viability in a mantle cell lymphoma cell line harboring ATM R2832C in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 34911817). | 34911817 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04497116 | Phase Ib/II | RP-3500 + Talazoparib RP-3500 | Study of RP-3500 in Advanced Solid Tumors | Recruiting | USA | GBR | DNK | CAN | 0 |
| NCT04589845 | Phase II | Alectinib Divarasib Entrectinib RP-3500 | Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | Recruiting | USA | POL | NZL | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BRA | BEL | AUS | 10 |
| NCT05566574 | Phase Ib/II | RP-3500 | A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer | Recruiting | USA | 0 |
CKB BOOST